{"id": "RL33288", "inputs": [{"text": "the u.s. government regulates the marketing of pharmaceuticals and agricultural chemicalsin the interest of public health .", "tokens": ["the", "u.s.", "government", "regulates", "the", "marketing", "of", "pharmaceuticals", "and", "agricultural", "chemicalsin", "the", "interest", "of", "public", "health", "."], "sentence_id": 1, "word_count": 17}, {"text": " ( 33 ) under this regime , the developer of a new drug - - known as its\"sponsor\" - - must demonstrate that the product is safe and effective before it can be distributed tothe public .", "tokens": ["(", "33", ")", "under", "this", "regime", ",", "the", "developer", "of", "a", "new", "drug", "-", "-", "known", "as", "its", "''", "sponsor", "''", "-", "-", "must", "demonstrate", "that", "the", "product", "is", "safe", "and", "effective", "before", "it", "can", "be", "distributed", "tothe", "public", "."], "sentence_id": 2, "word_count": 40}, {"text": "this showing requires a sponsor to conduct both preclinical and clinical investigationsof drugs that have not been previously tested .", "tokens": ["this", "showing", "requires", "a", "sponsor", "to", "conduct", "both", "preclinical", "and", "clinical", "investigationsof", "drugs", "that", "have", "not", "been", "previously", "tested", "."], "sentence_id": 3, "word_count": 20}, {"text": " ( 34 ) in deciding whether to issue marketing approval or not , the fdaevaluates the test data that the sponsor submits in a so - called new drug application ( nda ) .", "tokens": ["(", "34", ")", "in", "deciding", "whether", "to", "issue", "marketing", "approval", "or", "not", ",", "the", "fdaevaluates", "the", "test", "data", "that", "the", "sponsor", "submits", "in", "a", "so", "-", "called", "new", "drug", "application", "(", "nda", ")", "."], "sentence_id": 4, "word_count": 34}, {"text": "the fda maintains the test data incorporated into a nda in confidence .", "tokens": ["the", "fda", "maintains", "the", "test", "data", "incorporated", "into", "a", "nda", "in", "confidence", "."], "sentence_id": 5, "word_count": 13}, {"text": " ( 35 ) in addition , because therequired test data is ordinarily quite costly to generate , sponsors of new pharmaceuticals ordinarilydo not disclose them to the public .", "tokens": ["(", "35", ")", "in", "addition", ",", "because", "therequired", "test", "data", "is", "ordinarily", "quite", "costly", "to", "generate", ",", "sponsors", "of", "new", "pharmaceuticals", "ordinarilydo", "not", "disclose", "them", "to", "the", "public", "."], "sentence_id": 6, "word_count": 29}, {"text": "otherwise the sponsor's competitors could file their own ndasusing that test data , and thereby avoid the expenses of developing the information themselves .", "tokens": ["otherwise", "the", "sponsor", "'s", "competitors", "could", "file", "their", "own", "ndasusing", "that", "test", "data", ",", "and", "thereby", "avoid", "the", "expenses", "of", "developing", "the", "information", "themselves", "."], "sentence_id": 7, "word_count": 25}, {"text": " ( 36 ) prior to the introduction of the hatch - waxman act , federal law contained no separateprovisions addressing generic versions of brand - name drugs that the fda had previously approvedfor marketing .", "tokens": ["(", "36", ")", "prior", "to", "the", "introduction", "of", "the", "hatch", "-", "waxman", "act", ",", "federal", "law", "contained", "no", "separateprovisions", "addressing", "generic", "versions", "of", "brand", "-", "name", "drugs", "that", "the", "fda", "had", "previously", "approvedfor", "marketing", "."], "sentence_id": 8, "word_count": 35}, {"text": " ( 37 ) theresult was that a would - be generic drug manufacturer had to file its own nda in order to market itsdrug .", "tokens": ["(", "37", ")", "theresult", "was", "that", "a", "would", "-", "be", "generic", "drug", "manufacturer", "had", "to", "file", "its", "own", "nda", "in", "order", "to", "market", "itsdrug", "."], "sentence_id": 9, "word_count": 25}, {"text": " ( 38 ) some genericmanufacturers could rely on published scientific literature demonstrating the safety and efficacy ofthe drug .", "tokens": ["(", "38", ")", "some", "genericmanufacturers", "could", "rely", "on", "published", "scientific", "literature", "demonstrating", "the", "safety", "and", "efficacy", "ofthe", "drug", "."], "sentence_id": 10, "word_count": 19}, {"text": "because these sorts of studies were not available for all drugs , however , not all genericfirms could file these so - called paper ndas .", "tokens": ["because", "these", "sorts", "of", "studies", "were", "not", "available", "for", "all", "drugs", ",", "however", ",", "not", "all", "genericfirms", "could", "file", "these", "so", "-", "called", "paper", "ndas", "."], "sentence_id": 11, "word_count": 26}, {"text": " ( 39 ) further , at times the fda would request additional studies toaddress safety and efficacy questions that arose from experience with the drug following its initialapproval .", "tokens": ["(", "39", ")", "further", ",", "at", "times", "the", "fda", "would", "request", "additional", "studies", "toaddress", "safety", "and", "efficacy", "questions", "that", "arose", "from", "experience", "with", "the", "drug", "following", "its", "initialapproval", "."], "sentence_id": 12, "word_count": 29}, {"text": " ( 40 ) the resultwas that some generic manufacturers were forced to prove independently that their pharmaceuticalswere safe and effective , even though their products were chemically identical to those of previouslyapproved drugs .", "tokens": ["(", "40", ")", "the", "resultwas", "that", "some", "generic", "manufacturers", "were", "forced", "to", "prove", "independently", "that", "their", "pharmaceuticalswere", "safe", "and", "effective", ",", "even", "though", "their", "products", "were", "chemically", "identical", "to", "those", "of", "previouslyapproved", "drugs", "."], "sentence_id": 13, "word_count": 34}, {"text": "some commentators believed that the approval of a generic drug was a needlessly costly,redundant , and time - consuming process prior to the hatch - waxman act .", "tokens": ["some", "commentators", "believed", "that", "the", "approval", "of", "a", "generic", "drug", "was", "a", "needlessly", "costly", ",", "redundant", ",", "and", "time", "-", "consuming", "process", "prior", "to", "the", "hatch", "-", "waxman", "act", "."], "sentence_id": 14, "word_count": 30}, {"text": " ( 41 ) these observers noted thatalthough patents on important drugs had expired , manufacturers were not moving to introducegeneric equivalents for these products due to the level of resource expenditure required to obtainfda marketing approval .", "tokens": ["(", "41", ")", "these", "observers", "noted", "thatalthough", "patents", "on", "important", "drugs", "had", "expired", ",", "manufacturers", "were", "not", "moving", "to", "introducegeneric", "equivalents", "for", "these", "products", "due", "to", "the", "level", "of", "resource", "expenditure", "required", "to", "obtainfda", "marketing", "approval", "."], "sentence_id": 15, "word_count": 37}, {"text": " ( 42 ) as the introduction of generic equivalents often causes pricesto decrease , the interest of consumers was arguably not being served through these observed costsand delays .", "tokens": ["(", "42", ")", "as", "the", "introduction", "of", "generic", "equivalents", "often", "causes", "pricesto", "decrease", ",", "the", "interest", "of", "consumers", "was", "arguably", "not", "being", "served", "through", "these", "observed", "costsand", "delays", "."], "sentence_id": 16, "word_count": 29}, {"text": " ( 43 ) in response to these concerns , the hatch - waxman act created a new type of application formarket approval of a drug .", "tokens": ["(", "43", ")", "in", "response", "to", "these", "concerns", ",", "the", "hatch", "-", "waxman", "act", "created", "a", "new", "type", "of", "application", "formarket", "approval", "of", "a", "drug", "."], "sentence_id": 17, "word_count": 26}, {"text": "this application , termed an \"abbreviated new drug application\" ( anda ) , may be filed at the fda .", "tokens": ["this", "application", ",", "termed", "an", "``", "abbreviated", "new", "drug", "application", "''", "(", "anda", ")", ",", "may", "be", "filed", "at", "the", "fda", "."], "sentence_id": 18, "word_count": 22}, {"text": " ( 44 ) an anda may be filed if the active ingredient of the genericdrug is the bioequivalent of the approved drug .", "tokens": ["(", "44", ")", "an", "anda", "may", "be", "filed", "if", "the", "active", "ingredient", "of", "the", "genericdrug", "is", "the", "bioequivalent", "of", "the", "approved", "drug", "."], "sentence_id": 19, "word_count": 23}, {"text": "an anda allows a generic drug manufacturer torely upon the safety and efficacy data of the original manufacturer .", "tokens": ["an", "anda", "allows", "a", "generic", "drug", "manufacturer", "torely", "upon", "the", "safety", "and", "efficacy", "data", "of", "the", "original", "manufacturer", "."], "sentence_id": 20, "word_count": 19}, {"text": "the availability of the andamechanism often allows a generic manufacturer to avoid the costs and delays associated with filinga full - fledged nda .", "tokens": ["the", "availability", "of", "the", "andamechanism", "often", "allows", "a", "generic", "manufacturer", "to", "avoid", "the", "costs", "and", "delays", "associated", "with", "filinga", "full", "-", "fledged", "nda", "."], "sentence_id": 21, "word_count": 24}, {"text": "andas also allow a generic manufacturer , in many cases , to place itsfda - approved bioequivalent drug on the market as soon as any relevant patents expire .", "tokens": ["andas", "also", "allow", "a", "generic", "manufacturer", ",", "in", "many", "cases", ",", "to", "place", "itsfda", "-", "approved", "bioequivalent", "drug", "on", "the", "market", "as", "soon", "as", "any", "relevant", "patents", "expire", "."], "sentence_id": 22, "word_count": 29}, {"text": " ( 45 ) the hatch - waxman act placed certain limits upon the ability of generic competitors toreference the data generated by the manufacturers of brand - name drugs .", "tokens": ["(", "45", ")", "the", "hatch", "-", "waxman", "act", "placed", "certain", "limits", "upon", "the", "ability", "of", "generic", "competitors", "toreference", "the", "data", "generated", "by", "the", "manufacturers", "of", "brand", "-", "name", "drugs", "."], "sentence_id": 23, "word_count": 30}, {"text": "these limitations - - termedmarketing exclusivities - - consist of a period of time during which a competitor's ability to obtainfda permission to sell a generic version of a previously approved brand - name drug is restricted .", "tokens": ["these", "limitations", "-", "-", "termedmarketing", "exclusivities", "-", "-", "consist", "of", "a", "period", "of", "time", "during", "which", "a", "competitor", "'s", "ability", "to", "obtainfda", "permission", "to", "sell", "a", "generic", "version", "of", "a", "previously", "approved", "brand", "-", "name", "drug", "is", "restricted", "."], "sentence_id": 24, "word_count": 39}, {"text": "the federal food and drug laws establish several different sorts of marketing exclusivities , relatingto new chemical entities , new clinical studies , orphan drugs , and pediatric studies .", "tokens": ["the", "federal", "food", "and", "drug", "laws", "establish", "several", "different", "sorts", "of", "marketing", "exclusivities", ",", "relatingto", "new", "chemical", "entities", ",", "new", "clinical", "studies", ",", "orphan", "drugs", ",", "and", "pediatric", "studies", "."], "sentence_id": 25, "word_count": 30}, {"text": " ( 46 ) this report describes eachof these marketing exclusivities below .", "tokens": ["(", "46", ")", "this", "report", "describes", "eachof", "these", "marketing", "exclusivities", "below", "."], "sentence_id": 26, "word_count": 12}, {"text": "two decades of experience with the hatch - waxman act have resulted in diverse opinionsconcerning the system of incentives for innovation within the pharmaceutical industry .", "tokens": ["two", "decades", "of", "experience", "with", "the", "hatch", "-", "waxman", "act", "have", "resulted", "in", "diverse", "opinionsconcerning", "the", "system", "of", "incentives", "for", "innovation", "within", "the", "pharmaceutical", "industry", "."], "sentence_id": 27, "word_count": 26}, {"text": "aspharmaceutical firms may obtain patents from the uspto , some observers question the need for thefda to grant marketing exclusivities as well .", "tokens": ["aspharmaceutical", "firms", "may", "obtain", "patents", "from", "the", "uspto", ",", "some", "observers", "question", "the", "need", "for", "thefda", "to", "grant", "marketing", "exclusivities", "as", "well", "."], "sentence_id": 28, "word_count": 23}, {"text": " ( 95 ) other observers essentially take the opposite view , asserting thatthe marketing exclusivities available under u.s. law should be lengthened to match europeanstandards .", "tokens": ["(", "95", ")", "other", "observers", "essentially", "take", "the", "opposite", "view", ",", "asserting", "thatthe", "marketing", "exclusivities", "available", "under", "u.s.", "law", "should", "be", "lengthened", "to", "match", "europeanstandards", "."], "sentence_id": 29, "word_count": 26}, {"text": " ( 96 ) issueshave also arisen with respect to the use of marketing exclusivities to encourage the private sector todevelop bioterrorism countermeasures , as well as whether other nations are obligated by worldtrade organization ( wto ) agreements to grant marketing exclusivities similar to u.s. law .", "tokens": ["(", "96", ")", "issueshave", "also", "arisen", "with", "respect", "to", "the", "use", "of", "marketing", "exclusivities", "to", "encourage", "the", "private", "sector", "todevelop", "bioterrorism", "countermeasures", ",", "as", "well", "as", "whether", "other", "nations", "are", "obligated", "by", "worldtrade", "organization", "(", "wto", ")", "agreements", "to", "grant", "marketing", "exclusivities", "similar", "to", "u.s.", "law", "."], "sentence_id": 30, "word_count": 47}, {"text": "thisreport reviews these issues in turn .", "tokens": ["thisreport", "reviews", "these", "issues", "in", "turn", "."], "sentence_id": 31, "word_count": 7}, {"text": "in combination , patents and marketing exclusivities provide the fundamental framework ofintellectual property incentives for pharmaceutical innovation in the united states .", "tokens": ["in", "combination", ",", "patents", "and", "marketing", "exclusivities", "provide", "the", "fundamental", "framework", "ofintellectual", "property", "incentives", "for", "pharmaceutical", "innovation", "in", "the", "united", "states", "."], "sentence_id": 32, "word_count": 22}, {"text": "due to thetrips agreement's obligation of technological neutrality with respect to the patent system , ( 127 ) marketing exclusivitiesprovide congress with a more flexible option for stimulating specific sorts of desirable privateactivity than do patents .", "tokens": ["due", "to", "thetrips", "agreement", "'s", "obligation", "of", "technological", "neutrality", "with", "respect", "to", "the", "patent", "system", ",", "(", "127", ")", "marketing", "exclusivitiesprovide", "congress", "with", "a", "more", "flexible", "option", "for", "stimulating", "specific", "sorts", "of", "desirable", "privateactivity", "than", "do", "patents", "."], "sentence_id": 33, "word_count": 38}, {"text": "as such , marketing exclusivities have been , and likely will continue to be,the most viable option for encouraging the development of discrete classes of products regulated bythe fda .", "tokens": ["as", "such", ",", "marketing", "exclusivities", "have", "been", ",", "and", "likely", "will", "continue", "to", "be", ",", "the", "most", "viable", "option", "for", "encouraging", "the", "development", "of", "discrete", "classes", "of", "products", "regulated", "bythe", "fda", "."], "sentence_id": 34, "word_count": 32}, {"text": "the potential for expanded use of marketing exclusivities in turn raises a number ofinnovation policy issues .", "tokens": ["the", "potential", "for", "expanded", "use", "of", "marketing", "exclusivities", "in", "turn", "raises", "a", "number", "ofinnovation", "policy", "issues", "."], "sentence_id": 35, "word_count": 17}, {"text": "in the united states , marketing exclusivities are viewed primarily assupplementing patent protection , in that they provide more limited protections for inventions thatdo not meet patent act requirements , or effectively delay the onset of patent litigation for inventionsthat do .", "tokens": ["in", "the", "united", "states", ",", "marketing", "exclusivities", "are", "viewed", "primarily", "assupplementing", "patent", "protection", ",", "in", "that", "they", "provide", "more", "limited", "protections", "for", "inventions", "thatdo", "not", "meet", "patent", "act", "requirements", ",", "or", "effectively", "delay", "the", "onset", "of", "patent", "litigation", "for", "inventionsthat", "do", "."], "sentence_id": 36, "word_count": 42}, {"text": " ( 128 ) expanding the availability of marketing exclusivities , in addition to lengthening their term toeuropean levels , increases the possibility that marketing exclusivities will trump patents as theprimary form of intellectual property protection for certain fda - regulated products .", "tokens": ["(", "128", ")", "expanding", "the", "availability", "of", "marketing", "exclusivities", ",", "in", "addition", "to", "lengthening", "their", "term", "toeuropean", "levels", ",", "increases", "the", "possibility", "that", "marketing", "exclusivities", "will", "trump", "patents", "as", "theprimary", "form", "of", "intellectual", "property", "protection", "for", "certain", "fda", "-", "regulated", "products", "."], "sentence_id": 37, "word_count": 42}, {"text": "the decisionto supplant the primacy of the current regime of uspto - procured and judicially enforced patentrights with a system of automatic , fda - administered marketing exclusivities presents a number oftrade - offs that policy makers may wish to consider .", "tokens": ["the", "decisionto", "supplant", "the", "primacy", "of", "the", "current", "regime", "of", "uspto", "-", "procured", "and", "judicially", "enforced", "patentrights", "with", "a", "system", "of", "automatic", ",", "fda", "-", "administered", "marketing", "exclusivities", "presents", "a", "number", "oftrade", "-", "offs", "that", "policy", "makers", "may", "wish", "to", "consider", "."], "sentence_id": 38, "word_count": 42}, {"text": "among them are the impact of the contemplatedexclusivity periods upon both the incentives for pharmaceutical innovation and the availability ofmedications to consumers ; the desirability of individualized determinations about the technicalmerits of the pharmaceutical invention ; and whether the uspto or fda is the better institution forawarding proprietary rights to pharmaceutical innovators .", "tokens": ["among", "them", "are", "the", "impact", "of", "the", "contemplatedexclusivity", "periods", "upon", "both", "the", "incentives", "for", "pharmaceutical", "innovation", "and", "the", "availability", "ofmedications", "to", "consumers", ";", "the", "desirability", "of", "individualized", "determinations", "about", "the", "technicalmerits", "of", "the", "pharmaceutical", "invention", ";", "and", "whether", "the", "uspto", "or", "fda", "is", "the", "better", "institution", "forawarding", "proprietary", "rights", "to", "pharmaceutical", "innovators", "."], "sentence_id": 39, "word_count": 53}, {"text": "international harmonization provides another significant issue with respect to marketingexclusivities .", "tokens": ["international", "harmonization", "provides", "another", "significant", "issue", "with", "respect", "to", "marketingexclusivities", "."], "sentence_id": 40, "word_count": 11}, {"text": "even as some commentators have expressed concerns over the use of ftas toencourage trading partners to establish marketing exclusivities at domestic levels , others observe thateuropean levels of protection are substantially longer than their hatch - waxman analogues .", "tokens": ["even", "as", "some", "commentators", "have", "expressed", "concerns", "over", "the", "use", "of", "ftas", "toencourage", "trading", "partners", "to", "establish", "marketing", "exclusivities", "at", "domestic", "levels", ",", "others", "observe", "thateuropean", "levels", "of", "protection", "are", "substantially", "longer", "than", "their", "hatch", "-", "waxman", "analogues", "."], "sentence_id": 41, "word_count": 39}, {"text": "futuredialogue may concern setting global marketing exclusivity standards in view of national goals andpriorities .", "tokens": ["futuredialogue", "may", "concern", "setting", "global", "marketing", "exclusivity", "standards", "in", "view", "of", "national", "goals", "andpriorities", "."], "sentence_id": 42, "word_count": 15}, {"text": "finally , policy makers may appreciate that general patent reform legislation has been thesubject of significant discussion during the 109th congress .", "tokens": ["finally", ",", "policy", "makers", "may", "appreciate", "that", "general", "patent", "reform", "legislation", "has", "been", "thesubject", "of", "significant", "discussion", "during", "the", "109th", "congress", "."], "sentence_id": 43, "word_count": 22}, {"text": " ( 129 ) current legislativeproposals do not appear to impact the fundamental landscape of patents and marketing exclusivitieswithin the pharmaceutical industry .", "tokens": ["(", "129", ")", "current", "legislativeproposals", "do", "not", "appear", "to", "impact", "the", "fundamental", "landscape", "of", "patents", "and", "marketing", "exclusivitieswithin", "the", "pharmaceutical", "industry", "."], "sentence_id": 44, "word_count": 22}, {"text": "because legislative reform efforts are still underway , however,congressional attention to the impact of broadly oriented patent reforms upon the pharmaceuticalindustry may be appropriate .", "tokens": ["because", "legislative", "reform", "efforts", "are", "still", "underway", ",", "however", ",", "congressional", "attention", "to", "the", "impact", "of", "broadly", "oriented", "patent", "reforms", "upon", "the", "pharmaceuticalindustry", "may", "be", "appropriate", "."], "sentence_id": 45, "word_count": 27}], "section_names": ["", "introduction to the patent system", "fundamentals of marketing exclusivity", "innovation policy issues", "concluding observations"], "section_lengths": [0, 0, 26, 5, 14]}